Early assessment of the probable biological importance of drug targets, the potential market size of a successful new drug, and possible treatment side effects are critical for risk management in drug development. A comprehensive molecular epidemiology analysis involving thousands of well-characterized human tissues will thus provide vital information for strategic decision-making. Tissue microarray (TMA) technology is ideally suited for such projects. The simultaneous analysis of thousands of tissues enables highly standardized, fast and affordable translational research studies of unprecedented scale.:
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ddtec.2004.08.003 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!